BioStock: Aptahem’s Q4 lays groundwork for clinical studies

During the last quarter of 2021, Aptahem took further steps towards being able to initiate phase I clinical studies with the drug candidate Apta-1 in 2022, primarily by initiating production of GMP-certified drug substance. At the beginning of January, this was followed up by a signed start up agreement with an international clinical contract research organisation for the clinical development phase.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/aptahems-q4-lays-groundwork-for-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se